LOS ANGELES, Oct. 11, 2024 – Glancy Prongay & Murray LLP (“GPM”) announces that investors with substantial losses have the opportunity to lead the securities fraud class action lawsuit against Outset Medical, Inc. (“Outset Medical” or the “Company”) OM.
Understanding the Lawsuit
Class Period: August 1, 2022 – August 7, 2024
Lead Plaintiff Deadline: October 28, 2024
If you wish to serve as the lead plaintiff of the Outset Medical lawsuit, you can submit your contact information. You can also contact Charles H. Linehan of GPM to learn more about your rights.
The complaint filed alleges that throughout the Class Period, Defendants failed to disclose several key pieces of information to investors.
Key Allegations
The allegations include marketing Tablo products for a use not approved by the FDA, the likelihood of needing additional FDA approval, potential cessation of Tablo products sales, lack of sales team readiness, adverse impact on revenue growth, and misleading positive statements about the Company’s business.
To be a member of the class action, you need not take any action at this time. Contacting GPM can provide more information about the lawsuit and your rights.
Contact Information
For any inquiries or information regarding the lawsuit, contact Glancy Prongay & Murray LLP in Los Angeles, California.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Stay Updated
Follow Glancy Prongay & Murray LLP on LinkedIn, Twitter, and Facebook for updates on the lawsuit.
This article was sourced from Glancy Prongay & Murray LLP.
